– LentiGlobin in transfusion-dependent β-thalassemia (TDT) planned to be filed for marketing authorization in 2018 – – bb2121 in relapsed/refractory multiple myeloma planned to be filed for marketing ...
As the chart shows, the stock price benefited from three large jumps in June, August, and December. Here's how it went down. In June, at the annual American Society of Clinical Oncology (ASCO) meeting ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T ...
ATLANTA — Bluebird Bio (BLUE) only discloses gene therapy data on its inherited blood disorder programs twice each year, so expectations — and risks — run high each time the biotech reveals its cards.
Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and ...
In June, at the annual American Society of Clinical Oncology (ASCO) meeting, Bluebird and its partner Celgene (CELG +0.00%) presented data from the first 15 multiple myeloma patients treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results